Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase III Clinical Study to Assess Efficacy of PMZ-1620 Along With Standard Treatment in Patients of Acute Ischemic Stroke

NCT04047563 is registered in ClinicalTrials.gov with Pharmazz, Inc. as lead sponsor.

NCT NCT04047563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04047563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase III Clinical Study to Assess Efficacy of PMZ-1620 Along With Standard Treatment in Patients of Acute Ischemic Stroke
Lead sponsor
Pharmazz, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 10, 2019
Completion date
February 10, 2022
Enrollment
158 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral infarction, cerebral ischemia, stroke, acute